Alice Randon

Alice (born in 1999) holds a Master’s degree in pharmaceutical biotechnology from the University of Milan. After graduation, she joined the National Insitute of Molecular Genetics (INGM) in Milan as a lab manager, here she contributed to the development of engineered extracellular vesicles for personalized leukemia therapy. In August 2025, Alice joined Astherna as a Marie Curie PhD fellow within the EFFecT consortium. Her research focuses on identifying antisense oligonucleotides to slow or halt the progression of age-related macular degeneration (AMD).